Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 24, Issue 4, 2008, Pages 199-206

  Thomann, Robert ^a   Rossinelli, Nadia ^a   Keller, Ulrich ^a   Tirri, Brigitte Frey ^a   De Geyter, Christian ^a   Ruiz, Juan ^b   Kränzlin, Marius ^a   Puder, Jardena J ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Gestational diabetes; Inflammation; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

ADIPONECTIN; ALGESTONE; C REACTIVE PROTEIN; SEX HORMONE BINDING GLOBULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANOVULATION; ARTICLE; BLEEDING; BLOOD SAMPLING; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; LEUKOCYTE; MEASUREMENT; NEUTROPHIL; OBESITY; OVARY POLYCYSTIC DISEASE; PARAMETER; PHENOTYPE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; BODY FAT DISTRIBUTION; CASE-CONTROL STUDIES; CHRONIC DISEASE; DIABETES, GESTATIONAL; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPIDS; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PREGNANCY; REPRODUCTIVE HISTORY; SEX HORMONE-BINDING GLOBULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41649090561     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590801893398     Document Type: Article

References (51)

1. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;166:2081-2086.
2. Carmina E, Azziz R. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S7-S8.
3. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
4. Zawadzki JK DA. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome, Boston (MA): Blackwell; 1992. pp. 377-384.
5. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005;83:1717-1723.
6. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S13-S14.
7. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-2478.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
9. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:6014-6021.
10. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455.
11. Vgontzas AN, Trakada G, Bixler EO, Lin HM, Pejovic S, Zoumakis E, Chrousos GP, Legro RS. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea. Metabolism 2006;55:1076-1082.
12. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L,Nardo LG, Labella D, Savastano S, Russo T, et al. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2-5.
13. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53.
14. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131-137.
15. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
16. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004;53:2353-2358.
17. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
18. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
19. Lo JC, Feigenbaum SL, Escobar GJ, Yang J, Crites YM, Ferrara A. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 2006;29:1915-1917.
20. Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 1999;94:194-197.
21. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 2005;90:3983-3988.
22. Di Benedetto A, Russo GT, Corrado F, Di Cesare E, Alessi E, Nicocia G, D'Anna R, Cucinotta D. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 2005;28:34-38.
23. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pacini G, Funahashi T, Kautzky-Willer A. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004;27:1721-1727.
24. Kousta E, Efstathiadou Z, Lawrence NJ, Jeffs JA, Godsland IF, Barrett SC, Dore CJ, Penny A, Anyaoku V, Millauer BA, et al. The impact of ethnicity on glucose regulation and the metabolic syndrome following gestational diabetes. Diabetologia 2006;49:36-40.
25. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. Diabetes Care 1993;16:1598-1605.
26. Kaufmann RC, Schleyhahn FT, Huffman DG, Amankwah KS. Gestational diabetes diagnostic criteria: long-term maternal follow-up. Am J Obstet Gynecol 1995;172:621-625.
27. Koivunen RM, Juutinen J, Vauhkonen I, Morin-Papunen LC, Ruokonen A, Tapanainen JS. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001;86:2591-2599.
28. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-1150.
29. Anttila L, Karjala K, Penttila RA, Ruutiainen K, Ekblad U. Polycystic ovaries in women with gestational diabetes. Obstet Gynecol 1998;92:13-16.
30. Gestational diabetes mellitus. Diabetes Care 2004;27(Suppl 1):S88-S90.
31. Voigt M, Schneider KTM, Jährig K. Analyse des Geburtsgutes des Jahrgangs 1992 der Bundesrepublik Deutschland. Teil 1: Neue Perzentilwerte für die Körpermasse von Neugeborenen. Geburtshilfe Frauenheilkd 1996;56:550-558.
32. Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, De Geyter C, Keller U, Puder JJ. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and overweight women. J Clin Endocrinol Metab 2005;90:3230-3225.
33. Puder JJ, Blum CA, Mueller B, Geyter C, Dye L, Keller U. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Invest 2006;36:58-64.
34. Puder JJ, Varga S, Nusbaumer CP, Zulewski H, Bilz S, Muller B, Keller U. Women with polycystic ovary syndrome are sensitive to the TNF-α-lowering effect of glucose-induced hyperinsulinaemia. Eur J Clin Invest 2006;36:883-889.
35. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
36. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830.
37. Moriconi N, Kraenzlin M, Muller B, Keller U, Nusbaumer CP, Stohr S, Tamm M, Puder JJ. Body composition and adiponectin serum concentrations in adult patients with cystic fibrosis. J Clin Endocrinol Metab 2006;91:1586-1590.
38. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84:1932-1937.
39. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
40. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005;90:2545-2549.
41. de Zegher F, Ibanez L. Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S4-S5.
42. Codner E, Escobar-Morreale HF. Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2007;92:1209-1216.
43. de Boer JA, Lambalk CB, Hendriks HH, van Aken C, van der Veen EA, Schoemaker J. Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome. Hum Reprod 2004;19:504-509.
44. Premoli AC, Santana LF, Ferriani RA, Moura MD, De Sa MF, Reis RM. Growth hormone secretion and insulin-like growth factor-1 are related to hyperandrogenism in nonobese patients with polycystic ovary syndrome. Fertil Steril 2005;83:1852-1855.
45. Abbasi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism 2002;51:235-237.
46. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996;39:298-305.
47. Kajaia N, Binder H, Dittrich R, Oppelt PG, Flor B, Cupisti S, Beckmann MW, Mueller A. Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007;157:499-507.
48. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
49. Aroda V, Ciaraldi TP, Chang SA, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril 2007 Aug 11 [Epub ahead of print].
50. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med 2006;44:1264-1268.
51. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;61:738-746.